Edwards Lifesciences (EW) Revenue — Quarter Ended Dec 31, 2025
Revenue increased in the reporting quarter. The growth was against both the immediately preceding quarter and the same quarter one year earlier.
Key takeaway
Quarter ended Dec 31, 2025 · FY2025 Q4
Revenue increased in the reporting quarter. The growth was against both the immediately preceding quarter and the same quarter one year earlier.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$1.6B
Revenue reported for this quarter.
Quarter-over-quarter
+1.1%
Change from the immediately preceding quarter.
Year-over-year
+13.3%
Change from the comparable year-ago quarter.
Trailing four quarters
$6.1B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Mar 31, 2025 | $1.4B | +6.2% |
| Jun 30, 2025 | $1.5B | +11.9% |
| Sep 30, 2025 | $1.6B | +14.7% |
| Dec 31, 2025 | $1.6B | +13.3% |
Revenue performance
The company's revenue rose during the quarter, reflecting continued upward momentum.
Quarterly comparison
Compared to the immediately preceding quarter, revenue posted a modest increase. On a year-over-year basis, the growth was more substantial.
What to watch
The company's foreign earnings repatriation strategy and its impact on liquidity remain a point to monitor.